ArticleNeuroSci2026
The BLTT (Bonn Leistungs Tracking Test) in Patients with Temporal Lobe Gliomas-Feasibility of a Novel Neurocognitive Test Battery.
Article in NeuroSci, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeurocognitive testing in neuro-oncological patients often relies on time-intensive batteries with limited feasibility in this patient cohort. We evaluated the feasibility of the Bonn Leistungs Tracking Test (BLTT), a time-efficient screening tool assessing episodic memory, semantic memory, and executive functions in patients with high-grade temporal lobe gliomas.
methodsTwenty patients undergoing resection of temporal high-grade glioma between 2019 and 2022 underwent preoperative cognitive assessment using either the BLTT or a comprehensive neuropsychological battery routinely applied in temporal lobe epilepsy surgery.
resultsTwelve patients (60%) underwent the BLTT, and eight (40%) underwent the standard neuropsychological test battery. The BLTT was feasible in all 12 individuals (0% drop-out), whereas only four of eight patients (50% drop-out) were able to complete the standard battery. The mean BLTT total score was 69.3 (SD 4.5), indicating impaired neurocognitive performance relative to normative data. The BLTT provided evaluable domain-specific measures across episodic memory, semantic memory, and executive functioning despite the high discontinuation rate observed with standard testing.
conclusionsThe BLTT showed high feasibility for preoperative neurocognitive testing in patients with temporal high-grade gliomas. Its brief administration time and consistent applicability across relevant cognitive domains support its utility for routine neurocognitive assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.